APA (7th ed.) Citation

DM, O., M, N., BJ, M., T, M., M, H., A, K., . . . I, L. (2022). Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(7), 762. https://doi.org/10.1200/JCO.21.02067

Chicago Style (17th ed.) Citation

DM, O'Malley, et al. "Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40, no. 7 (2022): 762. https://doi.org/10.1200/JCO.21.02067.

MLA (9th ed.) Citation

DM, O'Malley, et al. "Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 7, 2022, p. 762, https://doi.org/10.1200/JCO.21.02067.